PRLog (Press Release) –
Apr 04, 2008 – RNL Bio, a leading stem cell firm, announced that the Korean FDA has granted the approved to begin the clinical study by plastic surgeons from Asan Medical Center in collaboration with the firm. There is no cure that can stop the progress of the ailment that results in tissue wasting. Reconstructive or microvascular surgery on affected region is generally offered to repair facial tissue. Recently, fat grafts have been suggested but most of the transplanted tissue disintegrates within three months. According to the preclinical study conducted by RNL Bio, scientists found that fat grafting with fat derived mesenchymal stem cells lasted longer and showed higher graft success than fat only grafting as reported in other studies.
In this study, patients will be treated using their own stem cells manufactured by RNL Bio and followed up for a year. A representative of the firm said “This study is expected to give hope to patients suffering from an obstinate impairment by providing a stem cell therapy developed by RNL Bio.”
About Romberg’s Disease
Romberg's disease or Parry Romberg Syndrome, also known as progressive hemifacial atrophy, is characterized by a pathological process involving progressive loss of the skin, fat, muscle and occasionally, bones of the face. Ten per cent of such patients undergo bilateral progression. It is a rare disease that causes severe facial deformation and impairs the patient’s social life as well. Parry and Romberg first described the disease in the eighteenth century and named the disease after themselves.
About RNL Bio Co Ltd.
RNL Bio is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul with a recently opened state-of-the-
art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In 2006 RNL established wholly owned US subsidiary, RNL Biostar, for clinical development in the US and for licensing its technologies in North and South America.
